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ABSTRACT
Background: An increasing number of
injectable biologics are now available for the
treatment of psoriasis. However, for individuals
who have never received this therapy, the
process of performing a self-injection can be
daunting. There is lack of patient educational
material on how to perform and optimize this
treatment.
Objective: The objective of this study is to
present a freely available online guide and
video on biologic injections that is informative
to patients and increases the success and
compliance of patients starting this therapy.
Methods: The self-injection technique taught
at the University of California—San Francisco
Psoriasis and Skin Treatment Center as well as
available information from the literature were
reviewed to design a practical guide for patients
receiving biologic injections.
Results: We created a printable guide and video
resource that describes how to improve the
injection process, pain management, travel
planning, and common concerns with biologic
injectables.
Conclusion: This guide is beneficial for patients
who wish to improve their experience with
biologic self-injections, for healthcare providers
who prescribe these treatments, and for trainees
learning about this modality.
Keywords: Adalimumab; Biologic agents;
Biologics; Etanercept; Ixekizumab; Patient
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INTRODUCTION
Psoriasis is a common chronic inflammatory
skin condition that affects 3–4% of the adult
United States population [1, 2]. The
pathogenesis of psoriasis is multifactorial and
thought to be a combination of genetic
susceptibility, immune dysregulation, and
environmental factors [3]. Key cytokines
involved in the pathogenesis of psoriasis
include tumor necrosis factor alpha (TNF-a)
and interleukins (IL-12, IL-17, IL-22, IL-23) [4].
In recent years, there has been a focus on the
development of treatment agents targeting
these inflammatory cytokines. Many of these
therapies are biologic injectable agents and are
administered via subcutaneous injection.
Biologic injectable agents currently available
for the treatment of moderate-to-severe plaque
psoriasis include the following: Etanercept
(Enbrel, Amgen Inc.), adalimumab (Humira,
AbbVie Inc.), ustekinumab (Stelara, Janssen
Biotech, Inc.), secukinumab (Cosentyx,
Novartis Pharmaceuticals Corporation) and
ixekizumab (Taltz, Eli Lilly and Company.).
These treatments have proven to be highly
efficacious in the treatment of psoriasis with
significant improvement seen in 50–75% of
patients and have become more commonly
used in clinical practice [5, 6]. Etanercept,
adalimumab, secukinumab, and ixekizumab
are each available in the form of either an
auto-injector pen or a prefilled syringe [7–10].
Ustekinumab is available only as a prefilled
syringe [11]. Below we will describe flow of
treatment, injection techniques, and practical
tips for biologic injectable agents.
METHODS
We reviewed the biologic injectable agent
protocol used at the University of California—
San Francisco Psoriasis and Skin Treatment
Center. In addition, the PubMed database was
searched using the term ‘‘psoriasis’’ combined
with the terms ‘‘biologic’’ ‘‘etanercept’’,
‘‘adalimumab, ‘‘ustekinumab’’, ‘‘secukinumab’’,
and ‘‘ixekizumab’’ to identify relevant articles to
design a comprehensive guide for patients
receiving biologic injectable treatment for
psoriasis.
This article does not involve any new studies
of human or animal subjects performed by any
of the authors. All photos are printed with the
consent of the subject(s).
RESULTS AND DISCUSSION
Overview
The guide below will cover the supplies needed
for biologic injectable agents, injection
procedure techniques, how to plan injections,
and how to travel with medications. Biologic
injectable agents have been demonstrated to be
effective treatments for psoriasis [12]. It is
important for patients and physicians to
discuss in detail the treatment options, patient
history, and patient preferences when
considering biologic injectable agents for the
treatment of psoriasis (Tables 1, 2).
Medication Management
The medication should be stored in a
refrigerator and kept at approximately 4 C
(39 F) to maintain its integrity. It should
never be frozen as this can inactivate the drug.
Unfortunately, patients commonly experience
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discomfort when injecting the medication that
has been stored at cold temperature. Therefore,
we recommend patients prepare their injection
by removing it from refrigeration and then
waiting 10–20 min for the medication to reach
room temperature. Additionally, it can be
helpful for patients to warm up the
medication in their hands to help reach a
more comfortable temperature for injection.
Target Injection Site Selection
Selection of the injection site is a personal
preference depending on what is the easiest for
each individual patient. We have found that
some sites are easier to inject than others (Fig. 1).
When choosing between the arm, abdomen, and
thighs many patients report that injecting in the
thighs is the easiest. This location tends to be
easier for several reasons. First, it is easily
accessible and is within arm’s reach. The thigh
can also be injected on either the right or left side
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Table 2 Workflow for injectable biologic agents
Removes medication from refrigeration
↓
Allow medication to reach room temperature
↓
Patient adequately numbs target injection site with ice pack
↓
Patient cleans and prepares target injection site with alcohol wipes
↓
Skin pinch technique used at target injection site
↓
Biologic injectable agent administered
↓
Syringes disposed of in an appropriate sharps container
Fig. 1 Locations for target injection sites
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without difficulty. In addition, this location
tends to be less painful than other injection
sites. Hence, thigh injection can be performed
while seated, which provides a flat surface and
allows for an easier set up.
Pain Management and Preparing
for Injection
Pain is a common concern for patients. An ice
pack (like the one that may come with the
medication upon delivery) can be used to help
numb the injection site prior to injection.
Patients can apply the ice pack to the area for
several seconds or until sufficiently numbed.
When the patient is ready to inject, the
injection site should be cleaned off with an
alcohol wipe prior to injection (Fig. 2).
Skin Pinch Technique
This technique involves pinching up excess skin
at the target injection site and injecting directly
into the pinched skin (Fig. 3). The thigh is a
viable option in almost all patients with proper
technique.
Administering the Medication
To administer the medication please follow the
instructions for the individual medication
(adalimumab, etanercept, ixekizumab,
secukinumab, ustekinumab). Medication is
best held in the dominant hand to maximize
control and dexterity during injection. Prefilled
syringes are best administered at a 45 angle to
the skin while using the skin pinch technique.
Auto-injector pens are best administered at a
90 angle to the skin. Make sure to review the
injection instructions unique to each
medication.
Injection Site Reactions
Injection site reactions are relatively common
side effects for injectable biologic agents. An
injection site reaction is redness, rash, swelling,
itching, or bruising at the site of injection.
Injection site reactions typically present within
a day after injection, and commonly resolve
within several days. It can be useful to ice the
area to reduce swelling and alleviate symptoms,
as well as use an antihistamine to reduce
swelling and itch.
Disposing of the Medication
After injection of the medication it is important
to dispose of syringes in an appropriate sharps
container. Sharps containers can be obtained at
a local pharmacy or at some doctors’ offices.
When the sharps container is full it can beFig. 2 Applying ice pack
Fig. 3 Skin pinch technique
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disposed of in safe container disposal sites
located at the doctors’ office and other
healthcare facilities. If a sharps container is
not available, a coffee tin can be used as an
alternative until a sharps container is acquired.
Traveling with Biologic
Injectable Medications
While we advise patients not to miss any
medication doses, sometimes it can be difficult
to maintain the injection schedule during times
of travel. There are several options to modulate
the injection regimen if the scheduled injection
happens to fall during travel time:
(a) For trips which will delay the injection by
less than 1 week of the scheduled injection
day, it is can be easier to defer the injection
until returning from the trip. This will
guarantee that the medication remains
adequately refrigerated and in optimal
condition without risking the integrity of
the medications during travel.
(b) For trips which will delay the injection by
more than 1 week of the scheduled injection
day, the patient will have to travel with the
medication. It is crucial to find adequate
storage and refrigeration for the medication
during travel. The medication should be
kept cold in an insulated bag with an ice
pack at all times. If the patient is traveling
on a long flight, a flight attendant may be
able to store the medication in the
refrigerator of the airplane. A doctor’s note
or copy of the prescription information can
be helpful when traveling through airport
security. Patients should make sure that
their accommodations at their travel
destination provide a secure place to
refrigerate the medication. The goal is to
ensure that that medication is safe, secure,
and at an adequate temperature.
Illness
While we advise patients not to miss any
medication doses, patients may encounter a
situation where their scheduled injection falls
during times of illness (flu, infection, fever, etc.)
Biologic agents are medications that can
modulate the immune system. Depending on
the severity of the illness, it is reasonable to
delay the injection until after recovering from
the illness; however, this should always be done
in consultation with a medical doctor.
CONCLUSIONS
Biologic injectable agents are safe and effective
treatment options for patients with
moderate-to-severe psoriasis, and while they
are becoming more common throughout
medical practice there has been a paucity of
guidance for patients and clinicians on how to
optimize the treatment experience. We hope
that this guide will be a valuable resource for
patients and clinicians preparing for treatment
with biologic injectable agents.
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